이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ZimVie 관리

관리 기준 확인 2/4

ZimVie's CEO는 Vafa Jamali, Feb2021 에 임명되었습니다 의 임기는 3.33 년입니다. 총 연간 보상은 $ 4.23M, 18.9% 로 구성됩니다. 18.9% 급여 및 81.1% 보너스(회사 주식 및 옵션 포함). 는 $ 4.11M 가치에 해당하는 회사 주식의 0.97% 직접 소유합니다. 4.11M. 경영진과 이사회의 평균 재임 기간은 각각 3 년과 2.3 년입니다.

주요 정보

Vafa Jamali

최고 경영자

US$4.2m

총 보상

CEO 급여 비율	18.9%
CEO 임기	3.3yrs
CEO 소유권	1.0%
경영진 평균 재임 기간	3yrs
이사회 평균 재임 기간	2.3yrs

최근 관리 업데이트

Recent updates

ZimVie: Guidance Suggests Company Fairly Valued At The Moment (Rating Downgrade)

Jun 04

ZimVie: Shrinking Its Way To Profitability

Feb 12

ZimVie Inc. (NASDAQ:ZIMV) Stock Catapults 93% Though Its Price And Business Still Lag The Industry

Dec 19

ZimVie Inc.'s (NASDAQ:ZIMV) Shares Bounce 27% But Its Business Still Trails The Industry

Apr 17

CEO 보상 분석

Vafa Jamali 의 보수는 ZimVie 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$51m
Dec 31 2023	US$4m	US$800k	-US$56m
Sep 30 2023	n/a	n/a	-US$58m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$38m
Dec 31 2022	US$10m	US$773k	-US$47m
Sep 30 2022	n/a	n/a	-US$94m
Jun 30 2022	n/a	n/a	-US$125m
Mar 31 2022	n/a	n/a	-US$121m
Dec 31 2021	US$8m	US$606k	US$16m

보상 대 시장: Vafa 의 총 보상 ($USD 4.23M )은 US 시장( $USD 2.46M ).

보상과 수익: Vafa 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Vafa Jamali (54 yo)

3.3yrs

테뉴어

US$4,226,944

보상

Mr. Vafa Jamali serves as Chief Executive Officer of ZimVie Inc. February 2021 and its President since December 2021. He serves as Director of ZimVie Inc. since March 2022. He joined Zimmer Biomet Holdings...

리더십 팀

이름	위치	테뉴어	보상	소유권
Vafa Jamali	President	3.3yrs	US$4.23m	0.97% $ 4.8m
Richard Heppenstall	Executive VP	2.8yrs	US$1.67m	0.30% $ 1.5m
Heather Kidwell	Senior VP	3yrs	US$1.07m	0.24% $ 1.2m
Indraneel Kanaglekar	Senior VP & Chief Commercial Officer	3yrs	US$1.14m	0.15% $ 733.2k
Sandra Schneider	Chief Accounting Officer	no data	데이터 없음	0.091% $ 453.9k
Steve Rondeau	Senior VP & Chief Information Officer	no data	데이터 없음	데이터 없음
Ann Vu	SVP & Chief Quality and Regulatory Affairs Officer	no data	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 관리: ZIMV 의 관리팀은 경험 ( 3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Vafa Jamali	President	2.3yrs	US$4.23m	0.97% $ 4.8m
Sally Crawford	Independent Director	2.3yrs	US$275.23k	0.15% $ 732.3k
David King	Independent Chairman of the Board	2.3yrs	US$410.23k	0.000010% $ 49.8
Richard Kuntz	Independent Director	2.3yrs	US$260.23k	0% $ 0
Vinit Asar	Independent Director	2.3yrs	US$270.23k	0% $ 0
Karen Matusinec	Independent Director	2.3yrs	US$280.23k	0% $ 0

2.3yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: ZIMV 의 이사회는 경험(평균 재직 기간 2.3 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

ZimVie 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

President exercised options and sold US$356k worth of stock

President exercised options and sold US$172k worth of stock

ZimVie Inc., Annual General Meeting, May 15, 2024

ZimVie Inc., Annual General Meeting, May 15, 2024

President exercised options and sold US$163k worth of stock

President recently bought US$122k worth of stock

Recent updates

Now 42% overvalued after recent price rise

Now 21% overvalued

ZimVie: Guidance Suggests Company Fairly Valued At The Moment (Rating Downgrade)

President exercised options and sold US$356k worth of stock

ZimVie Inc. Provides Earnings Guidance for the Full Year 2024 Ending December 31, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ZimVie Inc. to Report Q1, 2024 Results on May 08, 2024

President exercised options and sold US$172k worth of stock

H.I.G. Capital, LLC completed the acquisition of Zimmer Biomet Spine, Inc. from ZimVie Inc. (NasdaqGS:ZIMV).

ZimVie Inc., Annual General Meeting, May 15, 2024

ZimVie Inc., Annual General Meeting, May 15, 2024

President exercised options and sold US$163k worth of stock

Price target increased by 19% to US$16.00

New minor risk - Shareholder dilution

ZimVie Inc. Provides Earnings Guidance for First Quarter and Raises Earnings Guidance for the Full Year 2024

Full year 2023 earnings: EPS misses analyst expectations

ZimVie Inc. to Report Q4, 2023 Results on Feb 28, 2024

ZimVie: Shrinking Its Way To Profitability

ZimVie Inc. Announces Launch of Next-Generation TSX®? Implant in Japan

H.I.G. Capital, LLC entered into an Equity Purchase Agreement to acquire Zimmer Biomet Spine, Inc. from ZimVie Inc. (NasdaqGS:ZIMV) for approximately $380 million.

ZimVie Inc. (NASDAQ:ZIMV) Stock Catapults 93% Though Its Price And Business Still Lag The Industry

H.I.G. Capital, LLC entered into an Equity Purchase Agreement to acquire Zimmer Biomet Spine, Inc. from ZimVie Inc. (NasdaqGS:ZIMV) for approximately $380 million.

ZimVie Inc. Announces Compatibility Between Its Vital Spinal Fixation System and Brainlab Spine & Trauma Navigation

Third quarter 2023 earnings released: US$0.19 loss per share (vs US$0.032 profit in 3Q 2022)

Zimvie Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023

ZimVie Inc. Announces First U.S. Surgery with the 4.5mm Mobi-C(R) Cervical Disc

ZimVie Inc. Announces the Launch of Azure Multi-Platform Product Solutions

ZimVie Inc. to Report Q3, 2023 Results on Nov 01, 2023

ZimVie Inc. Announces the Recent Launch of Biotivity A/C Plus Membrane

ZimVie Announces FDA Approval to Launch Mobi-C® Hybrid Study

ZimVie Inc. Announces FDA Approval for New Mobi-C(R) Implant

Second quarter 2023 earnings released: US$0.89 loss per share (vs US$0.33 loss in 2Q 2022)

ZimVie Inc. Revises Financial Guidance for the Full Year Ending December 31, 2023

New minor risk - Share price stability

ZimVie Inc. to Report Q2, 2023 Results on Aug 02, 2023

First quarter 2023 earnings released: US$1.14 loss per share (vs US$0.98 loss in 1Q 2022)

Zimvie Inc. Revises Earnings Guidance for the Full Year 2023

ZimVie Inc.'s (NASDAQ:ZIMV) Shares Bounce 27% But Its Business Still Trails The Industry

President recently bought US$122k worth of stock

Full year 2022 earnings released: US$2.45 loss per share (vs US$3.66 loss in FY 2021)

ZimVie Inc. to Report Q4, 2022 Results on Mar 01, 2023

ZimVie Inc. Announces Over 200,000 Cervical Discs Have Been Replaced with Mobi-C

High number of new and inexperienced directors

ZimVie Inc. Reaffirms Revenue Guidance for the Year 2022

Zimvie Announces Launch of Next-Generation TSX™ Implant in the United States

ZimVie Inc. to Report Q3, 2022 Results on Nov 09, 2022

Zimvie Expands Navigation-Compatible Platform to Include Posterior Cervical Application

ZimVie Inc.(NasdaqGS:ZIMV) dropped from FTSE All-World Index (USD)

ZimVie: Disappointing Guidance Prompts Caution

Second quarter 2022 earnings released

ZimVie Inc. Revises Net Sales Guidance for the Year 2021

ZimVie Q2 Non-GAAP EPS beats, revenue down Y/Y, guidance reduced

ZimVie Inc. to Report Q2, 2022 Results on Aug 10, 2022

ZimVie: Undervalued Spin-Off

Zimvie Inc. Announces Launch of Two Next-Generation Dental Solutions in the United States

Executive VP recently bought US$205k worth of stock

High number of new and inexperienced directors

ZimVie: Spin-Off Of Dental And Spine Units Of Zimmer Biomet

ZimVie Inc. to Report Q1, 2022 Results on May 05, 2022

Forecast to breakeven in 2022

ZimVie Inc. Provides Revenue Guidance for the Year Ending December 31, 2022

High number of new and inexperienced directors

ZimVie Inc.(NasdaqGS:ZIMV) dropped from S&P 500 Health Care (Sector)

ZimVie Inc.(NasdaqGS:ZIMV) dropped from S&P Global 1200

ZimVie Inc. Announces Board of Directors

CEO 보상 분석

CEO

테뉴어

보상